Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
Background Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E/...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2020-09-01
|
| Colección: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Materias: | |
| Acceso en línea: | https://www.ahajournals.org/doi/10.1161/JAHA.119.016239 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|